Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease

By Van Patten Scott M.   Hughes Heather   Huff Michael R.   Piepenhagen Peter A.   Waire James   Qiu Huawei   Ganesa Chandrashekar   Reczek David   Ward Paul V.   Kutzko Joseph P.   Edmunds Tim  

Glycobiology, Vol. 17, Iss. 5, 2007-05 ,pp. : 467-478

Oxford University Press

Access to resources Recommend Favorite

Enzyme Replacement Therapy of Fabry Disease

By Clarke Joe T. R.   Iwanochko R. Mark  

Molecular Neurobiology, Vol. 32, Iss. 1, 2005-08 ,pp. : 43-50

Humana Press, Inc

Access to resources Recommend Favorite

Advances in the management of Anderson–Fabry disease:enzyme replacement therapy

By Thadhani Ravi   Pastores Gregory M  

Expert Opinion on Biological Therapy, Vol. 2, Iss. 3, 2002-03 ,pp. : 325-333

Informa Healthcare

Access to resources Recommend Favorite

Production in yeast of α -galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease

By Chiba Yasunori  

Glycobiology, Vol. 12, Iss. 12, 2002-12 ,pp. : 821-828

Oxford University Press

Access to resources Recommend Favorite

Enzyme replacement therapy for Fabry disease: lessons from two α-galactosidase A orphan products and one FDA approval

By Desnick Robert J  

Expert Opinion on Biological Therapy, Vol. 4, Iss. 7, 2004-07 ,pp. : 1167-1176

Informa Healthcare

Access to resources Recommend Favorite